Introduction
============

The use of bone stem cells has opened new prospects for the treatment of orthopaedic conditions characterized by large bone defects. An increasing number of *in vitro* and *in vivo* studies, and a few clinical investigations, have reported on the use of stem cells for bone regeneration so far. However, many questions of concern regarding bone stem cell usage exist to which answers are needed and before translating the basic biological knowledge and applying it into clinical practice, it is imperative that these issues are addressed. The Workshop 'Bone Stem Cells', organized in Bertinoro (Italy) on 7--10 October 2009, aimed to answer some of these questions. Particular issues addressed were the most suitable source of stem cell for bone regeneration, specific markers for the identification of adult bone stem cells, as well as the most suitable *in vitro* and *in vivo* models in order to predict clinical behaviour.

Sources of stem cells for bone regeneration
===========================================

A stem cell is a cell from the embryo, foetus or adult that is capable of asymmetric cellular divisions to parent and daughter cells and thus has the capacity of self-renewal and multipotent differentiation into specialized cells of the body. The most widely used sources of bone stem cells along with their advantages and drawbacks can be found in [Table 1](#tbl1){ref-type="table"}.

###### 

Advantages and disadvantages of the different sources of mesenchymal stem cells (MSC)

  **Source**                              **Advantages**                                                                                                       **Disadvantages**
  --------------------------------------- -------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------
  Embryonic stem cell                     Infinite lifespan, totipotency unlimited supply                                                                      Ethical concern, teratomas, requirement of animal-derived components during culture
  Induced pluripotent stem cells          Infinite lifespan, totipotency, unlimited supply, absence of ethical concern                                         Extremely specialized technique
  Bone marrow mesenchymal stromal cell    Absence of ethical concern                                                                                           Slow proliferation rate, limited life span, high variability in osteogenic potential, progressive loss of differentiative ability, immunogenicity
  Adipose tissue-derived stem cells       Absence of ethical concern, availability through procedure acceptable by patients                                    Immunogenicity, not yet fully understood differences with MSC
  Bone stem cells from peripheral blood   Absence of ethical concern, availability through procedure acceptable by patients                                    Low number, immunogenicity, not yet fully understood differences with MSC
  Stem cells from the umbilical cord      Absence of ethical concern                                                                                           Immunogenicity? Not yet fully understood differences with MSC
  Stem cells from amniotic fluid          Absence of ethical concern, high proliferative capacity, high differentiation potential                              Immunogenicity? Not yet fully understood differences with MSC
  Foetal osteoblasts                      Easy availability, fast growth rate, differentiation into mature osteoblasts, low immunogenicity, banking facility   

Immunogenicity refers to homologous use.

Embryonic stem cells (ESC) derive from the inner cells of the blastocyst and are characterized by high telomerase expression, normal and stable karyotype and the ability to form cells belonging to any of the three germ layers \[[@b1]--[@b3]\]. The ethical issue that impedes the application of hESC could be resolved through pluripotent (hESC-like) cells that do not require fertilization for their generation, but can be isolated from embryos developed directly from oocytes *via* parthenogenesis \[[@b4]\] or perhaps *via* somatic cell nuclear transfer. Recently, human-induced pluripotent stem cells were generated by the ectopic expression of ESC-specific transcription factors in somatic cells \[[@b5], [@b6]\].

Mesenchymal stem cells (MSC) derived from bone marrow are responsible for the maintenance of osteoblasts, osteocytes and bone lining cells throughout life and can be considered characteristic adult stem cells, and indeed cells with similar properties reside in virtually all postnatal organs and tissues. MSC have been isolated from bone marrow of iliac crest, femur \[[@b7]\], periosteum \[[@b8]\] and synovium \[[@b9]\]. Late plastic adherent MSC have recently shown to differentiate into osteoblasts \[[@b10]\].

Stem cells capable of multilineage differentiation similar to MSC were demonstrated in adipose tissue (ADSC) \[[@b11]\]. ADSC differentiated into functional osteoblasts when cultured on titanium \[[@b12]\], hydroxyapatite, cancellous human bone fragments or deproteinized bovine bone granules \[[@b13], [@b14]\].

In addition to the endothelial progenitor cells, circulating osteoblast-lineage cells were also isolated from human peripheral blood \[[@b15]\] and these cells formed ectopic bone when implanted in tissues *in vivo*\[[@b16]\].

MSC with osteogenic potential are present in the umbilical blood \[[@b17]\], umbilical cord perivascular cells \[[@b18]\] and Wharton's jelly \[[@b19]\].

A variety of different stem cell populations were described in human amniotic fluid (AFSC) \[[@b20]\], which, in turn, formed embryoid bodies \[[@b21]\], showed high proliferative capacity and differentiate along the adipogenic, osteogenic, myogenic, endothelial, neurogenic and hepatic pathways \[[@b22]\]. Human AFSC seeded onto scaffolds and cultured in osteogenic medium supported the formation of highly mineralized tissue upon implantation in immunodeficient mice, without teratoma formation \[[@b23]\].

Human foetal bone cells may be an alternative to MSC. Foetal osteoblasts have a doubling time comparable to MSC but start calcium deposition earlier \[[@b24], [@b25]\]. When seeded on porous scaffolds, they promoted bone repair in rats with critical size defects \[[@b26]\].

Stem cells, similar to bone marrow-derived MSC, were demonstrated in dental pulp \[[@b27]\]. Five different types of human dental stem/progenitor cells were isolated and characterized: dental pulp stem cells (DPSCs) ([Fig. 1](#fig01){ref-type="fig"}), stem cells from exfoliated deciduous teeth (SHED), periodontal ligament stem cells (PDLSCs), stem cells from apical papilla (SCAP) and dental follicle progenitor cells (DFPCs) \[[@b28]\]. Adult dental pulp contains precursors capable of forming odontoblasts \[[@b29]\]. Dental pulp progenitors have not been clearly identified but some data suggest that pericytes, which are able to differentiate into osteoblasts, could also differentiate into odontoblasts \[[@b30]--[@b32]\]. Recent findings demonstrated the isolation of mesenchymal progenitors from the pulp of human deciduous incisor. These cells were named SHED and exhibited a high plasticity because they could differentiate into neurons, adipocytes, osteoblasts and odontoblasts \[[@b33]\]. The periodontal ligament is a specialized tissue that contains STRO-1 positive cells and progenitors which can be activated to self-renew and regenerate other tissues such as cementum and alveolar bone \[[@b34]\]. Stem cells from the apical part of the human dental papilla exhibit a higher rate of proliferation and appear more effective than PDLSC for tooth formation \[[@b35]\]. Stem cells from the dental follicle express the stem cells markers Notch1, STRO-1 and Nestin \[[@b36]\]. Dental stem cells can differentiate into odontoblasts, adipocytes, neuronal-like cells, glial cells, osteoblasts, chondrocytes, melanocytes, myotubes and endothelial cells \[[@b37]\].

![Cultured dental pulp stem cells (DPSCs) show a mesenchymal stromal cell (MSC)-like spindle shape morphology.](jcmm0014-2614-f1){#fig01}

Markers for the identification of adult bone stem cells
=======================================================

Effective methods of cell sorting and cell enrichment are useful for isolating homogeneous cell preparations \[[@b38], [@b39]\]. However, the enrichment of MSC from a heterogeneous population is hampered by the lack of specific and unique markers. There is a general consensus that human MSC do not express the hematopoietic markers CD45, CD34, CD14 or CD11, the adhesion molecules CD31, CD18 (leucocyte function-associated antigen-1) or CD56 (neuronal cell adhesion molecule-1), rather, they express a set of non-specific markers: CD105 (SH2), CD73 (SH3/4), CD44, CD90 (Thy-1), CD71, STRO-1, CD106, CD166, ICAM-1, SB-10, CD29 \[[@b40]\] and CD146 \[[@b41]\]. None of these markers, either alone or in combination, are specific enough to achieve a high enrichment level from a heterogeneous population. STRO-1, which was extensively evaluated for the identification of bone stem cells, is not strictly specific because it is expressed in erythroid precursors \[[@b42]\].

MSC were found to express ESC transcription factors, such as OCT4, NANOG and SOX2 \[[@b43]\], which are associated with maintenance of multipotency. The stage-specific embryonic antigen-4 (SSEA-4), previously thought to be exclusively present on ESC, erythrocytes and some neural cells, were found in adult mesenchymal stem cell and can also be used to prospectively isolate MSC \[[@b44]\].

MSC have unique characteristics that prevent them from participation in prominent alloreactivity induction. MSC lack major histocompatibility complex MHC-II, show only minimal MHC-I expression and do not express the costimulatory molecules CD40, CD80 or CD86 \[[@b45]\].

Surface marker expressions may be influenced by species differences \[[@b46]\], tissue source \[[@b47], [@b48]\], isolation and culture methods \[[@b49]\]. *In vitro* expression of some markers by MSC did not always correlate with their expression patterns *in vivo*\[[@b50]\] and was influenced by the microenvironment \[[@b51]\].

Molecular aspects of bone stem cells
====================================

The specific differentiation pathways of MSC are guided in a complex multigenic process \[[@b52]\] under the control of key regulatory factors and transcriptional factors, such as runt-related transcription factor 2 (Runx2) and osterix \[[@b53]\].

Through microarray analysis of MSC differentiation into osteogenic lineage different gene clusters were associated with distinct stages, *i.e.* proliferation, matrix maturation and mineralization. The zinc finger and BTB domain containing 16 protein (ZNF145) has been identified as an upstream regulator of Runx2, with a crucial role in the initiation of osteoblastic differentiation \[[@b54]\]. The homeobox gene MSX2, which is implicated in osteoprogenitor cell function, was up-regulated during the whole period of differentiation. Alkaline phosphatase (ALP), collagen Type X alpha 1, bone morphogenetic protein 1, insulin-like growth factor 2, bone sialoprotein, periostin, C-type lectin domain family 3, osteoprotegerin and osteonectin were up-regulated during the intermediate and late phases of the osteogenic differentiation. Osteocalcin, which appeared only during matrix formation and mineralization phase, was a late marker \[[@b55]\], similarly to ID4, a member of the ID transcription factor family involved in cell cycle control \[[@b56]\], CRYAB (crystallin-αB), a small heat shock protein, \[[@b57]\] and SORT1 (sortillin 1), a multiligand type I receptor, that has been shown to promote extracellular matrix maturation \[[@b58]\].

Other factors implicated in the regulation of osteogenic differentiation of MSC include ATF4, SATB2, transforming growth factor-β (TGF-β), Hedgehog, fibroblast growth factor (FGF), ephrin and mitogen-activated protein kinases \[[@b59]\]. Osteocalcin, dermatopontin (DPT) and histamine receptor (HR1) are known downstream target for the vitamin D receptor (VDR) transcription complex, one of the drivers of osteoblast differentiation process \[[@b60]\]. Genes related to angiogenesis, through an angiopoietin and a vascular endothelial growth factor (VEGF)-dependent pathway, and to nervous system development, such as brain-derived neurotrophic factor, are up-regulated in MSC. A role of MSC in supporting vascularization and development of neuronal-like structures has been hypothesized \[[@b55], [@b57]\].

In parallel to gene expression analysis as a tool for understanding the molecular mechanisms underlying cell commitment, the study of post-transcriptional regulation has recently intensified. microRNAs (miRNAs) are small non-coding RNAs which bind the 3'UTR of mRNAs bearing fully or partially complementary sequences, therefore leading to either transcript degradation or translation inhibition \[[@b61]\]. Several authors have identified critical roles for miRNAs in bone cell differentiation and activity. Li *et al.* showed that BMP2-induced osteogenic differentiation of C2C12 cells is mediated both by the expression of miRNAs which inhibit muscle genes and by the down-regulation of 22 miRNAs which target osteoblast-specific genes constituting program of osteogenesis inhibition. In particular, miR-133 directly interacts with the master transcription factor Runx2 whereas miR-135 targets Smad5, a key mediator in osteogenic signal transduction \[[@b62]\]. A recent study revealed that bone marrow-derived MSC express miR-204/211 and that the level of these small non-coding RNAs increased when adipogenesis was induced; miR-204 is able to attenuate Runx2, thereby preventing osteogenesis, whereas the use of anti-miR-204 oligo increases ALP activity \[[@b63]\]. Micro-R-29b has been found to be up-regulated during the differentiation of MC3T3 mouse pre-osteoblastic cells; its expression inhibits a number of negative regulators of osteoblast differentiation which affect Smad, ERK, p38 MAPK and Wnt signalling pathways. Furthermore, miR-29b directly targets several collagen genes (COL1A1, COL5A3 and COL4A2), preventing fibrosis and facilitating extracellular matrix mineralization at late stages of differentiation \[[@b64]\]. Micro-R-29a and -29c interact with osteonectin mRNA and their increased expression during osteoblast differentiation *in vitro* correlates with the reduction of osteonectin protein during the mineralization process \[[@b65]\]. By employing a library of miRNA inhibitors, Schoolmeesters *et al.* identified miR-148b, miR-26a and miR-489 as key regulators of MSC osteogenic differentiation \[[@b66]\]. In a recent study, *in vitro* and *in vivo* evidence ascribed a critical role to miR-2861 in osteoblast differentiation. miR-2861 is able to induce osteoblast differentiation by targeting histone deacetylase 5 (HDAC5), which deacetylates Runx2, therefore enhancing its degradation. Moreover, the authors found that a homozygous mutation in the miR-2861 precursor which blocks the expression of the mature microRNA, contributed to the development of primary osteoporosis in two related adolescents \[[@b67]\].

Signaling pathways of osteoblast differentiation
================================================

β-Catenin, a central component of the cadherin cell adhesion complex, has an essential role in the Wingless/Wnt signaling pathway for osteoblast differentiation \[[@b68]\]. Wnt pathway is initiated through the binding of a Wnt ligand to the seven-transmembrane domain-spanning Frizzled receptor and the low-density lipoprotein receptor-related protein 5 and 6 (LRP5/6) co-receptors. As a consequence, cytosolic b-catenin escapes phosphorylation by glycogen synthase kinase (GSK)-3 β, which phosphorylation would be followed by degradation in the ubiquitin/proteasome pathway. As a result of Wnt pathway activation the now stabilized b-catenin translocates to the nucleus, binds to T cell factor/lymphoid enhancer binding factor (TCF/LEF) transcription factors, and regulates downstream gene expression. In human beings, the mutations in the Wnt co-receptor LRP5 lead to decreased or increased canonical Wnt signaling, which result in osteoporosis or a high bone mass phenotype, respectively. LRP5 mutations and the level of Wnt signalling were shown to determine the differentiation of hMSC into osteoblasts or adipocytes. Particularly, activating mutation T253I of LRP5 enhanced osteogenesis and inhibited adipogenesis, whereas inactivating mutation T244M of LRP5 exerted opposite effects \[[@b69]\].

Control of bone remodelling by the nervous system
=================================================

Bone remodelling is also under the influence of central and peripheral neural control \[[@b70]\]. Neuropeptide Y (NPY) and its receptors Y1 and Y2 were demonstrated in bone tissue. Osteoblasts, osteocytes and chondrocytes do not only synthesize NPY, but also peptidylglycine α-amidating monooxygenase (PAM), the enzyme responsible for NPY activation. NPY increased Y2 receptor mRNA in the mouse pre-osteoblast cell line MC3T3-E1, and decreased Y1 receptor mRNA of MSC. NPY significantly enhanced ALP activity and osteocalcin, but decreased calcium deposition \[[@b71]\]. In transthyretin (TTR) knockout mouse which overexpresses NPY as a result of PAM overexpression, increased bone mineral density and trabecular volume were observed. Simultaneously, significant increase of PAM expression in MSC occurred during osteogenic differentiation. Osteoblasts from TTR knockout mice showed higher ALP activity and higher osteopontin and osteocalcin mRNA expression, suggesting that increased neuropeptide Y content was related to increased bone mass \[[@b72]\].

*In vivo* models
================

One of the crucial aspects of bone engineering is the prediction of the bone healing capacity of the produced constructs. Although *in vitro* formation of mineral-like foci is generally considered indicative of an osteoprogenitor phenotype, a strict correlation between *in vitro* calcium deposition and *in vivo* mineralization was not consistently demonstrated \[[@b73]\]. To assess this correlation, ESC and ADSC were seeded on CultiSpher S microcarriers and then implanted into ectopic sites. Only heterogeneous bone formation, limited to specific areas, was obtained \[[@b74]\].

Moreover, *in vivo* models should evaluate if the osteogenesis induced by tissue engineering is similar to the physiological bone formation. A bone engineering approach should probably mimic the endochondral ossification, which is the physiological process for the repair of trabecular bone defects below the articular cartilage layer in long bones. An experimental model of this approach involved *in vitro* chondrocyte differentiation of mouse ESC seeded on a ceramic scaffold. After differentiation, the samples were implanted subcutaneously into immunodeficient mice. The implanted cartilage tissue matured, became hypertrophic and was ultimately replaced by bone tissue. This result demonstrated that a cartilage matrix was required for bone formation by ESC \[[@b75]\].

A similar approach taking use of chondrogenic pre-induction before implantation was also successful for MSC. A 6-week chondrogenic pre-induction of MSC seeded on β-TCP granules, before subcutaneous implantation into immunocompromised mice, resulted in endochondral ossification yielding ectopic bone. On the contrary, unprimed MSC underwent intramembranous bone formation. The origin of new bone from chondrogenic primed MSC most likely results of transdifferentiation of chondrocytes to osteoblasts, or of direct osteogenesis of cartilage-resident MSC \[[@b76]\].

Orthopaedic applications of bone stem cell technology
=====================================================

The orthopaedic application of bone stem cells may be of use when bone repair is impeded because of acquired or congenital \[[@b77]\] pseudoarthrosis, non-unions, large bone resections, significant traumas, local infection, previous irradiation or compromised vascularity.

In orthopaedics bone stem cells could be used in bone tissue engineering. There are five major types of bone engineering: (1) local stimulation of osteoprogenitor cells, (2) homing of osteoprogenitor cells, (3) transplantation of autologous osteoprogenitor cells to augment the local population, (4) transplantation of osteoprogenitor cells after culture expansion and (5) transplantation of fully formed tissue \[[@b78]\].

Local stimulation of proliferation and differentiation of resident osteoprogenitors requires a sufficient number of functionally active cells. Examples of local stimulation include the delivery of autologous or recombinant growth factors, biophysical stimulation, systemic pharmacological treatments and implantation of acellular scaffolds, where osteoprogenitor cells can adhere, proliferate and differentiate. The stimulation of local osteoprogenitors has the advantage that the regenerated tissue will have the same biological properties as the lost tissue \[[@b79]\]. However, local stimulation will most likely fail if subjected to debilitating healing conditions, such as infections, diabetes or necrosis which perhaps caused the bone defect in the first place.

Homing of osteoprogenitors refers to the recruitment of cells from the systemic circulation. In fact, it was recently demonstrated that osteogenic progenitor cells may travel through the systemic circulation \[[@b80]\]. According to this hypothesis, stem cell homing is a physiological process that may become the focus for new therapies to enhance the recruitment of osteo progenitors at bone repair sites.

Transplantation of autologous osteoprogenitors to augment the local population would be useful in clinical situations when complete healing is impeded by a local deficiency of stem cells. Transplantation of autologous bone marrow cells, after concentration by centrifugation, is an example of cell transplantation.

Transplantation of osteoprogenitor cells after culture expansion is similar to the technique already applied clinically for cartilage repair \[[@b81]\]. *In vitro* expansion generates a large number of osteoprogenitors, however, some variables can affect the clinical outcome, such as cell source, culture conditions and implantation procedure \[[@b82]\].

From the first report in 2001 concerning the implantation of MSC seeded on bioceramic scaffold in three patients with large bone defects \[[@b83]\], a number of clinical studies addressing engineered grafts in bone repair have been described, however, only few were prospective, randomized and controlled. A prospective, randomized, controlled study on the healing of high tibial osteotomy showed that MSC mixed with platelet-rich plasma and lyophilized bone chips had a higher osteogenic potential than lyophilized bone chips alone or in combination with platelet-rich plasma \[[@b84]\].

The use of MSC has also been proposed in bone marrow transplantation for the treatment of skeletal genetic diseases, such as osteogenesis imperfecta (OI) whereby transplanted donor cells migrate to the bone and form osteoblasts. OI patients with bone marrow transplantation showed new dense bone formation, an increase in total body bone mineral content, increases in growth velocity and reduced frequency of bone fracture \[[@b85]\]. *In utero* transplantation of adult MSC is a promising approach, as demonstrated in heterozygous BrtlIV knockin mice with a classical glycine substitution in type I collagen \[alpha1(I)-Gly349Cys\], dominant trait transmission and characterized by a phenotype similar to moderately severe and lethal OI \[[@b86]\].

Conclusions
===========

Without question, critical aspects of bone engineering, which may hamper a wider application, undoubtedly are the most suitable source of stem cell, specific markers for their identification and clear orthopaedic indications. Although adult bone marrow derived cells have been characterized and are extensively used, they have a limited developmental potential and loose their ability to proliferate and differentiate over time, thus presenting considerable drawbacks. On the other hand, embryonic stem cells have infinite lifespan and are unlimited in supply; however their use is not presently allowed in many countries because of ethical concerns. Stem cells from cord blood or from amniotic fluid are promising alternatives but more comprehensive knowledge of the differences with bone marrow cells needs to be achieved. Adipose tissue derived cells have been better investigated and could represent a useful cell population for bone engineering, even though some differences with bone marrow derived stromal cells should be taken into account. Foetal osteoblasts could have both the advantages of being more easily available than adult bone marrow cells and raising less ethical concerns than embryonic cells, but this approach requires further characterization.

Efforts should be focused on how to guide a stem cell from an uncommitted state to a more differentiated phenotype. No specific marker has been identified for osteogenic differentiation of adult stem cells. Moreover, it is necessary to compare *in vitro* and *in vivo* evidence.

Thus far, orthopaedic applications have been reported as case reports and controlled randomised trials are still lacking. Nevertheless, before drawing conclusive results from this clinical research, further biological aspects of bone stem cells should be elucidated and a general consensus on the best models, protocols and proper use of scaffolds and growth factors should be achieved.
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